[
    [
        {
            "time": "",
            "original_text": "上海医药(02607.HK)控股股东上实集团增持2万股H股",
            "features": {
                "keywords": [
                    "上海医药",
                    "控股股东",
                    "上实集团",
                    "增持",
                    "H股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海医药(02607.HK)控股股东上实集团增持2万股H股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "继续看好医药核心资产，坚守创新、消费和器械【西南医药|0901周报】",
            "features": {
                "keywords": [
                    "医药核心资产",
                    "创新",
                    "消费",
                    "器械",
                    "西南医药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "继续看好医药核心资产，坚守创新、消费和器械【西南医药|0901周报】",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【国元医药】2019H1汇总分析：业绩与行情分化持续，强者恒强 盈利能力下降",
            "features": {
                "keywords": [
                    "国元医药",
                    "2019H1",
                    "业绩",
                    "行情分化",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【国元医药】2019H1汇总分析：业绩与行情分化持续，强者恒强 盈利能力下降",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "288家药企晒上半年成绩单！17家营收超百亿，白云山、恒瑞、上药……净利润超20亿",
            "features": {
                "keywords": [
                    "药企",
                    "上半年",
                    "成绩单",
                    "营收",
                    "净利润",
                    "白云山",
                    "恒瑞",
                    "上药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "288家药企晒上半年成绩单！17家营收超百亿，白云山、恒瑞、上药……净利润超20亿",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【晨会聚焦】看好科技成长风格，把握正向预期差机会",
            "features": {
                "keywords": [
                    "晨会聚焦",
                    "科技成长",
                    "正向预期差",
                    "机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【晨会聚焦】看好科技成长风格，把握正向预期差机会",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]